Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt USD1740895493 ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
• The FDA issued a recall on Zantac because of high levels of the probable human carcinogen Nitrosodimethylamine (NDMA)
• Zantac failed to notify the public of this chemical in their product, choosing to gain profit rather than keep consumers safe
FDA removes Zantac from shelves over probable human carcinogen NDMA In April of 2020, the FDA determined that Zantac posed a risk to public health due to high amounts of the chemical NDMA. NDMA is a chemical used to make rocket fuel, as well as purposely induce cancer in lab animals for medical studies. NDMA is considered a probable human carcinogen by both the World Health Organization (WHO), and the U.S. Environmental Protection Agency (EPA).
The FDA permits a daily intake of 96 nanograms of NDMA, but testing revealed each tablet contained over 3,000,000 nanograms. That’s 3,000 times greater than the FDA’s intake limit.
The makers of Zantac have made billions from the drug, and had information that Zantac contained NDMA as early as 1981. They failed to warn consumers, doctors, or government regulators of the risk, and chose to gain profit rather than keep consumers safe.